European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.78% to 1,489.58 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion (EVAX), which climbed 15.3% and 11.2% respectively. They were followed by accommodations booking company trivago (TRVG) and biopharmaceutical company DBV Technologies (DBVT), which increased 7.4% and 4.4% respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and brewing company Anheuser-Busch InBev (BUD), which dropped 25% and 4.8% respectively. They were followed by telecommunications operator Telefonica (TEF) and pharmaceutical company Novo Nordisk (NVO), which lost 2.2% and 2.1% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and oil and gas company BP (BP), which rose 2% and 1.6% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and Bicycle Therapeutics (BCYC), which were up 1.2% and 0.8% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP), which plunged 65%, followed by biopharmaceutical company NuCana (NCNA), which was down 3.5%. They were followed by alcoholic beverage company Diageo (DEO) and biopharmaceutical company Amarin (AMRN), which fell 2.7% and 1.6% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.